MAYWOOD, IL-hepatitis C cures more than 90% of patients, but costs more than $ 50,000 per patient.
Data obtained from new studies can lead to significant cost savings. Preliminary data from the study of theoretical modeling researcher at the Chicago Stichic Medical School at the University of Loyola and the Loyola Medical University have shown that 50% of patients can reduce the standard 12-week treatment mode to less than six weeks without reducing their effectiveness.
"Hepatitis C has a potential to save up to 20 percent of C," said Loyola researcher Harel Dahari, PhD, MD Soroka University Medical Center MD. The first author of the joint study with Oed Edison. Senior Research Fellow – Amir Shlomai, Doctor of Medical Science, Beilinson Hospital in Israel.
The study was presented on November 12 at the Annual Meeting of the American Society for the Study of Liver Diseases in San Francisco.
Dr. Darius Dachy Loyola and Co-Chair of the Experimental and Theoretical Modeling Program (PETM) in the Department of Hepatology at the Chicago Stichc Medical School of the University of Loyola. Associate Professor of the Department of Loyola Medicine, Professor of the Department of Medicine at the University of Lyon, Susan Weychard, PhD, co-director of PETM and Associate Professor of Microbiology and Immunology Department, Scott Kotler. Chicago Strych Medical School.
Hepatitis C is an infection caused by contaminated blood. This can lead to liver damage, liver failure and liver malnutrition. About 70 million people worldwide, including about 3 million people in the United States, have Hepatitis C hepatitis.
The class of verbal drugs, called Directly-Used Antiviruses, has undergone a revolution in hepatitis C treatment. More than 90 percent of patients have the virus eliminated and treated with the least side effects. But limiting access to high value limits and significant financial burden for Medicare, Medicaid and individual insurers.
"At present, treatment is standardized, which is given for a certain period of time, usually for 12 weeks, does not adapt to individual patients," said Dr. Kotler.
In a new study, researchers used the so-called reactive-based therapy, which is based on modeling, to reduce the time needed for treatment. After several weeks of treatment, the researchers found that hepatitis C decreased. They used mathematical modeling to detect the complete disappearance of the virus.
To date, 22 patients have been included in the study. Mathematical modeling suggests that the patient can be reduced by 10 weeks in one patient (5 per cent of the total number of patients), eight patients (36 per cent) and eight weeks in six patients (nine per cent) in two patients. Other 11 patients (50%) needed treatment for a standard 12 weeks.
Twenty one patients were left without virus. The only recurrent patient was the hepatitis C virus, the most sophisticated treatment that was called genotype 3.
The proof of the concept shows that reductions in reaction time can be shortened by the pilot study. A big multi-media test is being conducted in Israel to prove the results.
In addition to reducing the costs, Dr. Darari said reduction of treatment modalities would facilitate the treatment of hepatitis C patients.
The study was conducted by David Yardey, MD, Anat Nevo-Shor, MD, Daniel Muntenu, MD and Nauk Abufreha, Massachusetts Gastroenterology and Liver Disease Department, Soroka University Medical Center, Beisheba, Israel; Assaf Issakhar, MD, Michal Cohen-Naphthalia, MD, Orly Snape Arbib, MD and Marius Braun, Livier Institute, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Orna Mor, PhD, Central Virology Laboratory, Ministry of Health, Sheba Medical Center, Israel.
Subject of the study: "50% of patients treated with HCA treatment with shortening treatment with DAA".
The study was supported by Clalit, Israel Health Organization and US National Institutes of Health.
Warning: AAAS and EurekAlert! EurekAlert is not responsible for correct news releases! It is intended for use by EurekAlert system or any other information.